NCT04441905View on ClinicalTrials.gov

Phase 1 Study of SAR440894 vs Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

August 22, 2024

Study Completion Date

August 22, 2024

Conditions
Chikungunya Virus Infection
Interventions
OTHER

Placebo

One time 60-minute IV infusion of lyophilized placebo for SAR440894

BIOLOGICAL

SAR440894

One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus

Trial Locations (3)

27710

Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham

32806

Pharmaceutical Product Development - Orlando Clinical Research Unit, Orlando

78744-1645

PPD - Austin Clinical Research Unit, Austin

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04441905 - Phase 1 Study of SAR440894 vs Placebo | Biotech Hunter | Biotech Hunter